Cytokinetics
CYTK
109 hedge funds and large institutions have $214M invested in Cytokinetics in 2014 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 38 increasing their positions, 27 reducing their positions, and 21 closing their positions.
73% more capital invested
Capital invested by funds: $123M → $214M (+$90.3M)
71% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 21
46% more call options, than puts
Call options by funds: $23.4M | Put options by funds: $16M
41% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 27
15% more funds holding
Funds holding: 95 → 109 (+14)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$6.34M |
| 2 |
RA
Royce & Associates
New York
|
+$6.33M |
| 3 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$6.22M |
| 4 |
SCM
Sigma Capital Management
Stamford,
Connecticut
|
+$4.97M |
| 5 |
SFM
Systematic Financial Management
Teaneck,
New Jersey
|
+$3.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$20.5M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$3.6M |
| 3 |
Millennium Management
New York
|
-$3.09M |
| 4 |
IG
ING Group
Amsterdam,
Netherlands
|
-$2.75M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.42M |
CYTK Hedge Fund Activity: Q1 2014 in Review
109 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2014, worth a combined $214M — up 73% from $123M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new CYTK positions and 21 closed out — a net gain of 15 holders — while 38 added to existing stakes and 27 trimmed.
The largest buyer was SAC Capital Advisors, opening a new position worth an estimated $6.34M. The largest seller was BVF Inc, cutting an estimated $20.5M.
- 109 institutional investors held Cytokinetics (CYTK) as of Q1 2014, up from 95 in Q4 2013.
- Funds reported $214M of Cytokinetics stock for Q1 2014, up 73% quarter-over-quarter.
- 36 funds opened new Cytokinetics positions in Q1 2014 and 21 closed out, a net change of +15 holders.
- The largest Cytokinetics buyer in Q1 2014 was SAC Capital Advisors, an estimated $6.34M added.
- The largest Cytokinetics seller in Q1 2014 was BVF Inc, an estimated $20.5M sold.
Based on aggregated 13F filings for Q1 2014.